SCHEMBL6780980

SCHEMBL6780980

COc1cc(C)c(C)cc1NC(=S)N1CCN(c2cccc(Cl)c2)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.61
MAPT P10636 7/20 0.57
ALDH1A1 P00352 4/20 0.57
KMT2A Q03164 5/20 0.57
MEN1 O00255 4/20 0.57
POLB P06746 2/20 0.57
NPC1 O15118 2/20 0.57
MAPK1 P28482 1/20 0.57
RAB9A P51151 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
LMNA P02545 2/20 0.56
RXFP1 Q9HBX9 1/20 0.56
HTT P42858 1/20 0.55
GAA P10253 2/20 0.54
ALOX15 P16050 1/20 0.54
TSHR P16473 1/20 0.54
RBP4 P02753 1/20 0.53
PKM P14618 1/20 0.53
HPGD P15428 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6960488 0.89 PHGDH (0.55) MAPTALDH1A1KMT2AMEN1POLB
SCHEMBL6961765 0.88 MEN1 (0.58) MAPTALDH1A1KMT2AMEN1POLB
SCHEMBL6959670 0.88 RBP4 (0.69) KDM4EMAPTALDH1A1KMT2AMEN1
SCHEMBL6780561 0.88 MEN1 (0.73) MAPTALDH1A1KMT2AMEN1POLB
SCHEMBL6776598 0.87 MEN1 (0.57) MAPTALDH1A1KMT2AMEN1POLB
SCHEMBL6896729 0.85 KMT2A (0.52) KDM4EMAPTALDH1A1KMT2AMEN1
SCHEMBL8699629 0.83 KDM4E (0.57) KDM4EMAPTALDH1A1KMT2AMEN1
SCHEMBL6783848 0.83 KMT2A (0.63) MAPTALDH1A1KMT2AMEN1POLB
SCHEMBL6782760 0.83 CYP3A4 (0.66) MAPTALDH1A1KMT2AMEN1POLB
SCHEMBL6956652 0.82 KMT2A (0.61) MAPTALDH1A1KMT2AMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6683184-B2 ANTITUMOR AGENTS SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2004-01-27 US disclosed
US-20030092910-A1 Piperazine derivatives and process for the preparation thereof SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2003-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092910-A1 Piperazine derivatives and process for the preparation thereof CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS KDM4E 2023/4885MAPT 4877/4885ALDH1A1 58/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.